As of May 2020, an emerging immune-mediated syndrome primarily affecting children has been detected primarily in Europe and the United States. The incidence of this syndrome appears to mirror the initial infectious assault, with a delay of several weeks. This syndrome has been termed multisystem inflammatory syndrome in children (MIS-C), and is observed in association with the coronavirus disease 2019 (COVID-19). The phenotypes of presentation include several characteristic features, including prolonged fever, eruption, neck stiffness and gastrointestinal manifestations with pronounced abdominal pain. Shock and organ dysfunction on presentation are frequently but inconsistent, while respiratory distress is typically, and notably, absent. We have reviewed recently published data aiming to better understanding MIS-C, with a focus on its mucocutaneous manifestations.
Mucocutaneous manifestations of MIS-C: conjunctivitis, oral mucosal changes, rash.
The rash of MIS-C is typically diffuse and non-specific.
Mucocutaneous manifestations of MIS-C are more common in younger children.
KD and MIS-C differ in mean age of onset, race predilection, and associated symptoms.